Taking aim at relapsed ovarian cancer patients considered incurable, Madrid, Spain-based PharmaMar SA is starting a Phase III trial with Yondelis (trabectedin), a compound first isolated from marine tunicates. (BioWorld International)

In what has proved to be a slow and somewhat bumpy road for gene therapy research, one company - Avigen Inc. - is gracefully bowing out in order to focus on more traditional drug development. (BioWorld Today)